A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
First Global Estimates of Pediatric
Just in time for World TB Day, a new study estimating the incidence of TB disease and MDR-TB in children has been published in the Lancet. The study is the first to make these estimates, conducting a systematic review and modeling age-specific regional notification data to conclude that 1,000,000 children developed tuberculosis disease, of whom 32,000 had MDR-TB in 2010. To read the abstract, click here.
Recent News and Announcements
An open letter has been sent to delamanid manufacturer, Otsuka, demanding increased access to the drug valuable in treating drug resistant forms of tuberculosis. The letter has been sent with signatories from around the world, urging the company to scale up its compassionate use program. Thus far, the company has made the drug available for [...]
Of the 9 million people a year who get sick with TB, a third of them are “missed” by public health systems. Read more about the Stop TB Partnership’s call to reach the three million here.
The third-largest private funder in global TB research, AstraZeneca, has announced it will no longer conduct early-stage research on tropical diseases, including tuberculosis and malaria. The company was a substantial contributor to TB R&D. Coupled with Pfizer’s discontinuation of anti-infectives research last year, the TB R&D pool of private investors continues to shrink. AstraZeneca’s decision [...]
A RESIST-TB and MSF collaboration entitled “Principles for designing future regimens for multidrug-resistant tuberculosis is featured in the January issue of the Bulletin of the World Health Organization. The publication outlines eight key principles for designing future treatment regimens to ensure that they will be clinically effective and programmatically practicable. View the publication here.
The US National Institute for Allergy and Infectious Diseases (NIAID) have scheduled to continue the webinar series on Clinical Research Design and Conduct. This program is being coordinated by the DMID International Clinical Studies Support Center (ICSSC) located at FHI 360. Session II of the Clinical Research Design series will be: Wednesday, 8 January 2014 [...]